Loading
A phase 2 trial of cabozantinib and atezolizumab in lung cancer, run by Jun Zhang, MD, PhD, not yet recruiting.
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) is a phase 2, interventional study registered as NCT05859217 by Jun Zhang, MD, PhD, with a registry enrolment figure of 40 participants, started 2024-12 and due to reach its primary completion in 2026-06. Interventions recorded: Cabozantinib; Atezolizumab. Conditions listed: Lung Cancer; NSCLC Stage IV; Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced NSCLC. Primary outcome: Objective response rate (ORR). Lung eligibility wording from the registry: "* Pathologically confirmed advanced/metastatic NSCLC, with PD-L1\<1% based on IHC using 22C3 antibody". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Exelixis, Cabozantinib, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.